Zacks Research Reduces Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Investment analysts at Zacks Research dropped their Q3 2026 earnings per share estimates for AngioDynamics in a research report issued to clients and investors on Tuesday, January 27th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.08). Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.03) EPS and Q2 2028 earnings at ($0.02) EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, Canaccord Genuity Group boosted their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Stock Down 0.3%

ANGO stock opened at $9.98 on Thursday. AngioDynamics has a twelve month low of $8.27 and a twelve month high of $13.99. The stock has a market capitalization of $411.38 million, a price-to-earnings ratio of -14.90 and a beta of 0.47. The firm’s fifty day simple moving average is $12.09 and its two-hundred day simple moving average is $11.07.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, January 6th. The medical instruments supplier reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The company had revenue of $79.43 million for the quarter, compared to the consensus estimate of $76.43 million. AngioDynamics had a negative net margin of 9.02% and a negative return on equity of 2.28%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.04) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS.

Institutional Trading of AngioDynamics

A number of large investors have recently modified their holdings of ANGO. Divisadero Street Capital Management LP grew its holdings in AngioDynamics by 253.7% during the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock worth $33,683,000 after acquiring an additional 2,435,365 shares in the last quarter. Weber Capital Management LLC ADV purchased a new stake in shares of AngioDynamics in the 4th quarter worth approximately $17,978,000. UBS Group AG lifted its position in shares of AngioDynamics by 83.6% in the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after purchasing an additional 501,881 shares during the period. Millennium Management LLC boosted its stake in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after purchasing an additional 393,682 shares in the last quarter. Finally, Bastion Asset Management Inc. increased its holdings in AngioDynamics by 31.8% during the third quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock valued at $13,442,000 after buying an additional 304,960 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Q2 operational momentum — Zacks highlights strong fiscal Q2 results, rising adoption of the NanoKnife system in prostate cancer and broad med‑tech tailwinds that could support improving margins and revenue growth. Reasons to Add AngioDynamics Stock to Your Portfolio for Now
• Positive Sentiment: Analyst upgrades to some forward quarters and FY outlook — Zacks raised estimates for Q1 2028, Q3 2027 and improved FY2027 EPS (from -$0.18 to -$0.13), signaling expectation of recovery in later periods. These upward revisions can be supportive for the stock if trends continue.
• Neutral Sentiment: Zacks maintains a “Strong‑Buy” rating — the firm is constructive on the name overall, but its published note shows a mix of raises and cuts across quarters, so the rating alone isn’t a clear directional catalyst.
• Neutral Sentiment: Short‑interest report appears anomalous — January data shows 0 shares reported and a 0.0 days‑to‑cover figure, which is likely a reporting artifact and not actionable by itself.
• Negative Sentiment: Multiple near‑term EPS cuts — Zacks trimmed several quarter estimates (notably Q3/Q4 2026 and Q2 2027 among others), including a sizable Q4 2026 cut; combined with company guidance for FY2026 that implies negative EPS, these downgrades increase the chance of continued short‑term pressure on the share price.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.